PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

Cytotoxic chemotherapies put patients at risk for future hematopoietic malignancies. Goodell and colleagues show that PPM1D mutations confer a survival advantage onto hematopoietic clones by rendering them resistant to DNA-damaging agents such as cisplatin. Selective pressures will be specific to different mutations and should be considered in choice of chemotherapy.

https://ift.tt/2P3tkbi